Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

Who May Qualify: - Participants of any sex and gender must be ≥ 40 years old at the time of signing the willing to sign a consent form. - Diagnosed with T2DM and requiring treatment - Established CV disease (ischaemic heart disease, cerebrovascular disease, peripheral arterial disease) - History of HTN and an SBP ≥ 130 mmHg at screening and ≥ 120 mmHg at the Randomisation Visit. - At least one additional risk factor for HF: - Age ≥ 70 years - UACR \> 20 mg/g - eGFR \< 60 mL/min/1.73 m2 - History of polyvascular disease (at least two of: ischaemic heart disease, cerebrovascular disease, and peripheral arterial disease) - History of atrial fibrillation or atrial flutter - NT-proBNP \> 125 ng/L Who Should NOT Join This Trial: - Previously confirmed diagnosis and treatment of heart failure - An eGFR \< 30 mL/min/1.73 m2 at screening - Known hyperkalaemia, defined as potassium ≥ 5.5 mmol/L within 3 months prior to screening - Type 1 diabetes mellitus or uncontrolled T2DM with HbA1c \> 10.5% (\> 91 mmol/mol) at screening - Serum sodium \< 135 mmol/L at screening, determined as per central laboratory assessment - Stroke, transient ischaemic cerebral attack, valve implantation or valve replacement, carotid surgery, carotid angioplasty, or cardiac surgery, within 3 months prior to randomisation - Myocardial infarction within 3 months prior to randomisation, or within 1 month prior to randomisation when there is no further planned revascularisation - Percutaneous coronary intervention within 1 month prior to randomisation - Known severe hepatic impairment, defined as Child-Pugh Class C, based on records that confirm documented medical history - Documented history of adrenal insufficiency - Any dialysis (including for acute kidney injury) within 3 months prior to screening - Any acute kidney injury within 3 months prior to screening - Prohibited concomitant medications Always talk to your doctor about whether this trial is right for you.